First-in-human phase I study of ISTH0036, an antisense oligonucleotide selectively targeting transforming growth factor beta 2 (TGF-β2), in subjects with open-angle glaucoma undergoing glaucoma filtration surgery

PURPOSE: To evaluate the safety and tolerability of intravitreal ISTH0036, an antisense oligonucleotide selectively targeting transforming growth factor beta 2 (TGF-β2), in patients with primary open angle glaucoma (POAG) undergoing trabeculectomy (TE; glaucoma filtration surgery). METHODS: In this...

Descripción completa

Detalles Bibliográficos
Autores principales: Pfeiffer, Norbert, Voykov, Bogomil, Renieri, Giulia, Bell, Katharina, Richter, Paul, Weigel, Melanie, Thieme, Hagen, Wilhelm, Barbara, Lorenz, Katrin, Feindor, Martin, Wosikowski, Katja, Janicot, Michel, Päckert, Daniela, Römmich, Regina, Mala, Carola, Fettes, Petra, Leo, Eugen
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Public Library of Science 2017
Materias:
Research Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5708654/
https://www.ncbi.nlm.nih.gov/pubmed/29190672
http://dx.doi.org/10.1371/journal.pone.0188899

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5708654/
https://www.ncbi.nlm.nih.gov/pubmed/29190672
http://dx.doi.org/10.1371/journal.pone.0188899

Ejemplares similares